Modal DNA-values in prostate cancer patients with deferred therapy or endocrine therapy.
Modal DNA-values were assessed with flow cytometry in 269 patients with newly detected untreated prostate cancer. One hundred and seventy-two patients with low-grade, low-stage, non-metastasized cancers were followed without treatment and in this group initial tumor ploidy had no prognostic value. Ninety-seven patients with clinically more advanced prostate cancers were subjected to endocrine therapy and in this group ploidy was prognostic regarding cancer-related survival.